Genotype-specific differences in short QT syndrome include variations in cardiac event timing and ECG features, with potassium channel blockers holding potential as a therapeutic strategy
The hidden burden: statewide trends in atrial fibrillation and flutter attributable to high systolic blood pressure in the United States (1990 to 2021)